Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS FEBRUARY ISSUE PUBLISHED
  • FEBRUARY 2021 Issue has been successfully launched on 1 February 2021.

Abstract

SGLT2 INHIBITORS: A NEW CLASS OF DRUGS FOR TYPE-II DIABETES MELLITUS

Lahari Samudrala*, T. Ramya Krishna, V. Sireesha and Pooja Agarwal 

ABSTRACT

Diabetes is on the rise. No longer a disease of predominantly rich nations, the prevalence of diabetes is steadily increasing everywhere, most markedly in the world’s middle-income countries. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new group of oral medications used for treating type II Diabetes Mellitus. The drugs work by helping the kidneys to lower the blood glucose levels. Globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population. This reflects an increase in associated risk factors such as being overweight or obese. Over the past decade, diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries. The present therapeutic classes of anti-diabetic drugs are not adequately effective in maintaining long-term glycemic control in the most patients. Sodium glucose transporter-2 (SGLT2) inhibitors including Dapagliflozin, Canagliflozin and Empagliflozin act by a novel insulin-independent mechanism by blocking glucose reabsorption in the proximal convoluted tubule resulting in markedly increased glycosuria, and blocking the formation of proteins.

Keywords: Canagliflozin, Dapagliflozin, Empagliflozin, Sodium Glucose Co-Transporter-2 Inhibitors.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More